Limits...
Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer.

Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Kim KM, Kang WK, Park JO - Transl Oncol (2015)

Bottom Line: Clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the IGFBP-3 promoter.Patients with a hypermethylated IGFBP-3 promoter had similar 8-year disease-free survival compared with those without a hypermethylated IGFBP-3 promoter (73% vs 75%, P = .78).In subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of patients with IGFBP-3 methylation as compared with those without IGFBP-3 methylation (8-year DFS: 55.6% vs 71.6%, P = .3694 and 8-year overall survival: 55.6% vs 68.4%, P = .491, respectively) even with no statistical significance.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

No MeSH data available.


Related in: MedlinePlus

IGFBP-3 methylation as measured by MS-PCR and MethyLight quantitativePCR in gastric cancer cell lines.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562974&req=5

f0005: IGFBP-3 methylation as measured by MS-PCR and MethyLight quantitativePCR in gastric cancer cell lines.

Mentions: IGFBP-3 methylation pattern was measured by MS-PCR in 22 known gastric cell lines (KATO-III, OCUM-2M, AGS, N87, MKN-1, MKN-28, MKN-45, MKN-74, YCC-1, YCC-2, YCC-3, YCC-7, SNU-1, SNU-5, SNU-16, SNU-216, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668, and SNU-719). The clinical information of these gastric cell lines was summarized in Table 1. In methylation analysis by MSP of IGFBP3, all gastric cell lines with methylated band revealed IGFBP3 methylation of more than 80% in quantitative PCR. The representative results are shown in Figure 1.


Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer.

Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Kim KM, Kang WK, Park JO - Transl Oncol (2015)

IGFBP-3 methylation as measured by MS-PCR and MethyLight quantitativePCR in gastric cancer cell lines.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562974&req=5

f0005: IGFBP-3 methylation as measured by MS-PCR and MethyLight quantitativePCR in gastric cancer cell lines.
Mentions: IGFBP-3 methylation pattern was measured by MS-PCR in 22 known gastric cell lines (KATO-III, OCUM-2M, AGS, N87, MKN-1, MKN-28, MKN-45, MKN-74, YCC-1, YCC-2, YCC-3, YCC-7, SNU-1, SNU-5, SNU-16, SNU-216, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668, and SNU-719). The clinical information of these gastric cell lines was summarized in Table 1. In methylation analysis by MSP of IGFBP3, all gastric cell lines with methylated band revealed IGFBP3 methylation of more than 80% in quantitative PCR. The representative results are shown in Figure 1.

Bottom Line: Clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the IGFBP-3 promoter.Patients with a hypermethylated IGFBP-3 promoter had similar 8-year disease-free survival compared with those without a hypermethylated IGFBP-3 promoter (73% vs 75%, P = .78).In subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of patients with IGFBP-3 methylation as compared with those without IGFBP-3 methylation (8-year DFS: 55.6% vs 71.6%, P = .3694 and 8-year overall survival: 55.6% vs 68.4%, P = .491, respectively) even with no statistical significance.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

No MeSH data available.


Related in: MedlinePlus